Arcutis Biotherapeutics, INC Schedule 13G passive stakes

Polar Capital Holdings Plc and Polar Capital LLP have reported beneficial ownership of 5.28% of Arcutis Biotherapeutics, Inc. common stock.

State Street Corporation has updated its beneficial ownership filing for Arcutis Biotherapeutics Inc., reporting a significant holding of common stock.

State Street Corporation has reported beneficial ownership of 5.1% of Arcutis Biotherapeutics Inc.'s common stock as of March 31, 2026.

Prudential Financial, Inc. filed an amendment to its Schedule 13G, reporting a 4.3% beneficial ownership stake in Arcutis Biotherapeutics, Inc.

Jennison Associates LLC has reported a 4.0% beneficial ownership in Arcutis Biotherapeutics Inc. common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Arcutis Biotherapeutics Inc. following an internal realignment.

Rubric Capital Management LP and David Rosen have disclosed a 6.75% beneficial ownership stake in Arcutis Biotherapeutics, Inc., holding 8,271,577 shares as of December 31, 2025.

Prudential Financial, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 5.7% in Arcutis Biotherapeutics, Inc. as of December 31, 2025.

Jennison Associates LLC has reported a 5.5% beneficial ownership stake in Arcutis Biotherapeutics Inc. common stock.

Jennison Associates LLC has reported an increased beneficial ownership of 10.2% in Arcutis Biotherapeutics Inc., holding 12,254,119 shares of common stock.

Polar Capital Holdings Plc and its affiliates have updated their beneficial ownership in Arcutis Biotherapeutics, Inc., reporting a 4.2% stake as of June 30, 2025.

Prudential Financial, Inc. has filed an amended Schedule 13G, reporting a 10.1% beneficial ownership stake in Arcutis Biotherapeutics, Inc. as of March 31, 2025.

Polar Capital Holdings Plc and its affiliates have disclosed a 5.65% beneficial ownership stake in Arcutis Biotherapeutics, Inc. common stock, held for passive investment purposes.

Jennison Associates LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 9.6% in Arcutis Biotherapeutics Inc. as of March 31, 2025.